Rheumatology Network Newsletter

To view this email as a web page, click here.

Potential New Lupus Treatment Passes Hurdle

Anifrolumab, a potential new for lupus, just successfully completed a phase three clinical trial in which patients demonstrated reduced disease activity by significant margins, according to a statement issued by the drug’s maker AstraZeneca.

FDA Approves Ixekizumab for Ankylosing Spondylitis

Rheumatology Network Editorial Staff Lilly has announced that it received FDA approval for Taltz (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyl oarthritis).

News Roundup from Rheumatology Network

In this week's rheumatology news roundup, we feature a Q&A with Dr. Aryeh M. Abeles who talks with Rheumatology Network about his concerns with the black box warning label for the gout treatment febuxostat. We also include a story on addressing prescription abdandonment in rheumatoloyg. These and other stories in today's news roundup.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.